Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
$10.38
0.0%
$10.29
$10.00
$10.44
$358.11MN/A243,128 shs123,678 shs
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
$10.61
+0.0%
$10.52
$10.10
$10.60
$357.40M0.01100,374 shs102 shs
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
$10.30
$10.24
$10.05
$10.35
$355.08MN/A96,429 shs185,844 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$10.93
$10.94
$10.46
$11.44
$38.39MN/A1,028 shs317 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
+0.10%-0.10%+1.27%+0.87%+1,038,999,900.00%
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
+0.05%+0.05%+0.71%+1.44%+1,058,999,900.00%
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
+0.01%+0.01%+0.45%+1.39%+1,030,099,900.00%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
0.00%-0.19%+0.09%+1.20%+4.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
$10.38
0.0%
$10.29
$10.00
$10.44
$358.11MN/A243,128 shs123,678 shs
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
$10.61
+0.0%
$10.52
$10.10
$10.60
$357.40M0.01100,374 shs102 shs
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
$10.30
$10.24
$10.05
$10.35
$355.08MN/A96,429 shs185,844 shs
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
$10.93
$10.94
$10.46
$11.44
$38.39MN/A1,028 shs317 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
+0.10%-0.10%+1.27%+0.87%+1,038,999,900.00%
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
+0.05%+0.05%+0.71%+1.44%+1,058,999,900.00%
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
+0.01%+0.01%+0.45%+1.39%+1,030,099,900.00%
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
0.00%-0.19%+0.09%+1.20%+4.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
1.00
SellN/AN/A
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
1.00
SellN/AN/A
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
1.00
SellN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest RFAI, CGCT, DMAA, and IPCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2026
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
Reiterated RatingSell (D+)
(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
N/AN/A$0.18 per share57.58($0.38) per shareN/A
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/A
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
N/AN/AN/AN/AN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
$6.22M$0.1954.68N/AN/AN/A-64.81%2.94%N/A
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
N/AN/AN/AN/AN/AN/AN/AN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest RFAI, CGCT, DMAA, and IPCX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
N/A$0.06N/A$0.06N/AN/A
5/14/2026Q1 2026
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
N/A$0.07N/A$0.07N/AN/A
3/30/2026Q4 2025
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
N/A-$0.06N/A-$0.06N/AN/A
3/21/2026Q4 2025
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
N/A$0.06N/A$0.06N/A$2.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
N/AN/AN/AN/AN/A
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
N/AN/AN/AN/AN/A
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
N/AN/AN/AN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/AN/AN/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Cartesian Growth Corp III stock logo
CGCT
Cartesian Growth Corp III
234.50 millionN/AN/A
Drugs Made In America Acquisition Corp. stock logo
DMAA
Drugs Made In America Acquisition
233.72 million33.41 millionN/A
Inflection Point Acquisition Corp. III stock logo
IPCX
Inflection Point Acquisition Corp. III
334.47 millionN/AN/A
RF Acquisition Corp II stock logo
RFAI
RF Acquisition Corp II
N/A3.51 million6.53 millionN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cartesian Growth Corp III stock logo

Cartesian Growth Corp III NASDAQ:CGCT

$10.38 0.00 (-0.01%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

We are a blank check company incorporated on October 29, 2024 as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout this prospectus as our initial business combination. We have not selected any business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target. Additionally, we have not contacted any of the prospective target businesses that Cartesian Growth Corporation (“CGC I”), a former special purpose acquisition company (“SPAC”) sponsored by affiliates of our sponsor that completed its initial business combination in January 2023, had considered and rejected while such entity was a blank check company searching for target businesses to acquire. We also have not contacted any of the prospective target businesses that Cartesian Growth Corporation II (“CGC II”), an existing SPAC sponsored by affiliates of our sponsor that consummated its initial public offering in May 2022, has considered while such entity continues its search for target businesses to acquire. However, we may contact any such targets subsequent to the closing of this offering if we become aware that the valuations, operations, profits or prospects of such target business, or the benefits of any potential transaction with such target business, would be attractive to our shareholders. We have conducted no operations and have generated no revenues to date, and we will not generate operating revenues until, at the earliest, after we consummate our initial business combination. While we may pursue our initial business combination in any business industry or sector, we intend to focus on seeking high-growth businesses with proven or potential transnational operations or outlooks in order to capitalize on the experience, reputation, and network of our management team. Furthermore, we intend to seek target businesses where we believe we will have an opportunity to drive ongoing value creation after our initial business combination is completed, as our management team has done with multiple investments over a wide range of sectors, industries and geographical locations. Although we anticipate acquiring a target business that is an operating business, we are not obligated to do so and may determine instead to merge with or acquire a company with no operating history if the terms of the transaction are determined by us to be favorable to our public shareholders and the target business has a fair market value of at least 80% of the assets held in the trust account (excluding the deferred underwriting commissions and taxes payable, if any, on the income accrued on the trust account) at the time of our signing a definitive agreement in connection with our initial business combination. In such event, investors would not have the benefit of basing the decision on whether to remain with our company following such transaction on the past operations of such target business. Furthermore, in such a situation, many of the acquisition criteria and guidelines set forth in this prospectus may be rendered irrelevant. If we do not obtain a fairness opinion from an independent investment banking firm or another independent entity that commonly renders valuation opinions with respect to such criteria, the fair market value of such a target would be determined by our board of directors based upon one or more standards generally accepted by the financial community, such as actual and potential sales, earnings, cash flow and/or book value, discounted cash flow valuation or value of comparable businesses. We can provide no assurances that our management team’s expertise will guarantee a successful initial business combination. In addition, our management team is not required to devote a significant or certain amount of time to our businesses and our management team is currently devoting time to, and is involved with, other businesses. Our sponsor is an affiliate of Cartesian Capital Group, LLC (“Cartesian”), a global private equity firm and registered investment adviser headquartered in New York City, New York. Cartesian has extensive experience providing growth capital to companies around the world. Since its inception in 2006, Cartesian has managed more than $3 billion in committed capital. Cartesian was founded by Peter Yu, who previously founded and served as Chief Executive Officer of AIG Capital Partners, Inc. (“AIGCP”), a leading international private equity firm with over $4.5 billion in committed capital. Cartesian’s team currently consists of 23 professionals, who together have more than 300 years of international private equity experience. Collectively, the Cartesian team has executed more than 55 market-leading investments across 30 countries. Over the years, the Cartesian team has developed an extensive network of relationships, particularly in North America, Europe, South America, and Asia, and an established record of innovative and opportunistic investing, consistent discipline, and significant value creation for all stakeholders. We believe our team has the required analytic, financial, and operational expertise to complete a successful initial business combination and generate attractive risk-adjusted returns for our shareholders. Our executive offices are located in New York, New York.

Drugs Made In America Acquisition stock logo

Drugs Made In America Acquisition NASDAQ:DMAA

$10.60 +0.01 (+0.05%)
Closing price 09:25 AM Eastern
Extended Trading
$10.60 0.00 (0.00%)
As of 09:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. To date, our efforts have been limited to organizational activities as well as activities related to this offering. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. While we may pursue a business combination target in any business, industry or geographical location, we intend to focus our search for businesses in the pharmaceutical industry. Our executive offices are located at 1 East Broward Boulevard, Suite 700, Fort Lauderdale, FL 33301 and our telephone number is (954) 870-3099.

Inflection Point Acquisition Corp. III stock logo

Inflection Point Acquisition Corp. III NASDAQ:IPCX

$10.30 0.00 (0.00%)
Closing price 06:32 AM Eastern
Extended Trading
$10.30 0.00 (0.00%)
As of 06:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a special purpose acquisition company incorporated on January 31, 2024, as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. We have not selected any specific business combination target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any business combination target with respect to an initial business combination with us. However, members of our management team had been actively in discussions with potential business combination partners in their capacity as officers and directors of Inflection Point Acquisition Corp. II (“IPXX”), and we may pursue business combination partners that had previously been in discussions with IPXX’s management team. While we may pursue an initial business combination in any industry, sector or geographic region, we intend to focus our search initially on North American and European businesses in disruptive growth sectors, which complements the expertise of our management team. Our company will combine the abilities of a diverse and founder-friendly management team. We have assembled a management team with experience across both public and private markets with deep roots in our target markets. Our team combines decades of experience sourcing, researching, and investing in complex transactions that create value for shareholders. We expect to seek an investment opportunity where each member of our management team can leverage their expertise and network to create significant value. We will seek fundamentally strong businesses in a broad range of disruptive growth sectors, with emphasis on one or more of the following attributes, although we may decide to enter into a business combination with a target business that does not have one or more of these attributes: • Innovative, technology-enabled company of scale focused on acquiring new customers with a large addressable market, legacy analogue competitors and a differentiated path to market or superior product. • Customer focused and deeply experienced team fueled by a shared connection and passion for the business. • Operates in an industry not typically active in traditional IPOs, but that our management feels public market investors will value and desire exposure to the public market. • Achieved a scale such that the profit contribution from existing business offsets fixed costs and is prepared to reinvest in high return on capital opportunities. • Adaptable to the rapidly changing business environment and major shift in demographics with the ability generate shareholder value in any market cycle. Our executive offices are located in New York, New York.

RF Acquisition Corp II stock logo

RF Acquisition Corp II NASDAQ:RFAI

$10.93 0.00 (0.00%)
As of 09:30 AM Eastern
This is a fair market value price provided by Massive. Learn more.

RF Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 5, 2024, and is headquartered in Singapore.